A2 Milk Shares Gain Bullish Analyst Coverage: Here’s The Look

Goldman Sachs analyst Peter Marks has initiated coverage of The a2 Milk Company shares (ASX:A2M) with a Buy rating and A$7.90 price target, marking a potential turning point for the embattled infant formula specialist after a turbulent start to 2026.

A2 Milk shares closed at A$6.78 on Tuesday, representing a 26% decline year-to-date but a remarkable 27.44% surge through the month of June alone.

The Goldman Sachs price target implies approximately 17% upside from current levels, suggesting markets may have overreacted to recent setbacks. The stock had traded as low as A$4.88 in early June following a voluntary product recall announcement, marking a near-40% year-to-date decline at that point before the recent recovery began.

The Recall That Triggered the Selloff

The catalyst for A2 Milk’s year-to-date underperformance emerged in early May when the company announced a voluntary recall of three batches of infant formula in the United States due to contamination with cereulide, a toxin likely originating from a contaminated ARA (arachidonic acid) ingredient in the supply chain. The affected batches were sold exclusively in the US market, representing a relatively small volume of total production.

Bell Potter analyst immediately flagged the brand-perception risk, noting that while the firm expected no material impact on FY26 financials from the recall itself, the company would likely need to increase marketing expenditure to reassure Chinese consumers and recapture any lost customers. The broker cut its price target from A$8.35 to A$6.75 and reiterated a Hold rating, emphasising that product recalls can damage brand equity even when the direct financial hit is limited.

Goldman Sachs Counters

Goldman Sachs’ contrarian Buy call centres on the thesis that A2 Milk’s business is “transitioning to a more robust model” and that the recent pullback presents a buying opportunity for investors willing to look past near-term noise. While the full research note has not yet been widely disseminated, the initiation represents a vote of confidence in the company’s multi-year strategic transformation.

That transformation has been underway since the company’s 2020-21 setback, when over-reliance on daigou resellers and limited supply-chain control led to significant earnings volatility. Since then, management has pursued greater in-sourcing of manufacturing, supply-chain diversification, and a more balanced channel strategy in China encompassing cross-border e-commerce, offline retail, and intermediary networks.

The strategy appears to be yielding results in underlying fundamentals. In FY23, the most recent full-year results available, revenue increased approximately 10% year-on-year to around NZ$1.59 billion, driven heavily by growth in China and the United States. Net profit after tax rose roughly 27%, with management guiding toward sustainable mid-teens EBITDA margins, a meaningful improvement in earnings quality compared to the volatile margins of prior years.

The company’s earnings calls have emphasised improved control over the value chain and more predictable demand patterns as the business matures beyond its initial rapid-growth phase. Management has framed the evolution as a shift from opportunistic distribution through grey-market channels toward a more institutionalised, brand-led approach that should deliver more consistent returns.

China Dependency

China and broader Asia remain the profit engine for A2 Milk, a concentration that presents both opportunity and risk. The company’s success in building brand recognition and distribution in China has been central to its growth story, but that dependence also exposes shareholders to regulatory shifts, competitive dynamics, and demographic trends beyond management’s control.

China’s infant formula market has become increasingly competitive as local brands improve quality and international players vie for share. Regulatory requirements, including GACC (General Administration of Customs China) registration for imported products, add layers of complexity. Meanwhile, China’s birth rate has been declining, creating a structurally smaller addressable market over time even as per-capita consumption of premium products may increase.

The recent recall incident, though occurring in the United States, illustrates how quickly brand perception can shift in categories where safety and trust are paramount. In infant formula, parents’ purchasing decisions are heavily influenced by perceived quality and safety, making any contamination headline a potential catalyst for customer churn.

Technical and Sentiment Inflection

The 27.44% surge in A2 Milk shares through June suggests a technical and sentiment inflection may be underway. After capitulating in early May around the recall announcement, the stock has staged a repair rally that has coincided with evidence of retail buying interest and, now, fresh institutional support via the Goldman Sachs initiation.

Technical traders would note that the stock is recovering from oversold conditions, with the sharp June bounce potentially marking a short-term bottom. However, longer-term holders remain cautious, with Australian retail trading forums reflecting a mix of bargain-hunting and lingering regret from those still nursing losses from prior cycles.

The question for markets is whether the current rally represents a durable shift in sentiment or merely a tactical bounce within a longer-term downtrend. The answer will likely depend on the next set of financial results and whether management can demonstrate that the recall was truly an isolated incident rather than a symptom of lingering supply-chain vulnerabilities.

Buy, Hold, or Sell?

The Goldman Sachs Buy rating stands in contrast to more cautious views elsewhere in the analyst community. Bell Potter’s Hold rating and A$6.75 price target reflects scepticism that the company has fully resolved its execution challenges. Catapult Wealth’s outright sell call in mid-May here on TheBull added to the chorus of caution, arguing that valuation remains unattractive even after the selloff.

This divergence creates an interesting setup for investors. Bulls can point to Goldman’s endorsement as validation that the strategic transformation is real and that the market has overshot to the downside. The firm’s “more robust model” language aligns with management’s own messaging about improved supply-chain control and channel diversification, suggesting that sophisticated investors see the long-term thesis intact.

Bears, meanwhile, can argue that elevated multiples relative to peers, ongoing China concentration risk, and mixed analyst sentiment justify continued caution. The recall episode demonstrated that idiosyncratic risks remain, and the next quality or regulatory issue could quickly undermine the recovery narrative.

The 27% June rally in a2 Milk shares has reset the technical picture and brought fresh attention to a name that many had written off earlier in the year, yet this is a battle that is far from over it seems.

Bull Case: